Related Experiment Videos
Death receptor 4 and bladder cancer risk
Aditi Hazra1, Robert M Chamberlain, H Barton Grossman
1Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer Research
|March 22, 2003
Summary
A specific genetic variation in death receptor 4 (DR4) is linked to a reduced risk of bladder cancer. This protective effect is more pronounced in younger individuals, women, and light smokers, suggesting a role in environmental susceptibility.
Area of Science:
- Molecular epidemiology
- Cancer genetics
- Apoptosis signaling
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) initiates apoptosis via death receptors DR4 and DR5.
- A common polymorphism in DR4 exon 4 (C/G at amino acid 626) alters the receptor's ligand-binding interface.
- Understanding genetic susceptibility to bladder cancer is crucial for public health.
Purpose of the Study:
- To investigate the association between the DR4 exon 4 polymorphism and bladder cancer risk.
- To explore potential interactions between this polymorphism and demographic or environmental factors.
Main Methods:
- Case-control study design involving Caucasian individuals.
- Genotyping for the DR4 exon 4 C/G polymorphism.
- Statistical analysis using odds ratios (OR) and confidence intervals (CI) to assess risk.
Main Results:
- The DR4 exon 4 G/G genotype demonstrated a significant overall decreased risk of bladder cancer (OR = 0.58).
- A stronger protective effect was observed in younger individuals (OR = 0.42) and women (OR = 0.45).
- The protective association was notably stronger in light smokers (OR = 0.19) compared to heavy smokers (OR = 0.83).
Conclusions:
- The DR4 exon 4 polymorphism is associated with reduced bladder cancer risk in Caucasians.
- This genetic variation may modulate susceptibility to environmental factors, such as smoking, in bladder cancer development.
- Findings suggest a role for DR4 genetic variants in the molecular epidemiology of bladder cancer.